Related Tags >> Genzyme Alemtuzumab Rebif Sanofi

Campath News

Most Popular Campath Story

Who's next on the biotech buyout hit list?

October 16, 2007 — 5:59am ET

Now that Biogen Idec is in play, the analysts are on the lookout for the next big acquisition target. Bear Stearns' Mark Read more...

Campath Press Releases

Phase I/II Clinical Trial in Chronic Lymphocytic Leukemia to Evaluate Combination Therapy with Biothera’s Imprime PGG
Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
PRESS RELEASE: Three-Year Analysis Demonstrates Significant Treatment Effect of Alemtuzumab

Latest Headlines

Post-merger Genzyme opens up the throttle on R&D plans
April 27, 2011
Sanofi goes back to the negotiation table with Genzyme
January 10, 2011
Genzyme's ($GENZ) Termeer ponders poison pills and CVRs
November 29, 2010
Genzyme says Sanofi's bid is $4.2B short of reality
October 25, 2010
Genzyme sees signs of remission in 5-year MS drug data
October 14, 2010
Positive MS data may thwart Icahn's plans for Genzyme
April 14, 2010
Genzyme gains MS drug rights in $2.8B deal
March 31, 2009
Who's next on the biotech buyout hit list?
October 16, 2007

Paid Research Reports

More Research Reports >>